Pearls and pitfalls in nonalcoholic fatty liver disease: tricky results are common

Abstract

Interpretation of diagnostic and surveillance laboratory results and imaging in liver disease is fraught with misinterpretation and/or uncertainty. Nonalcoholic fatty liver disease (NAFLD) represents an ever-growing proportion of liver disease cases but presents unique challenges for the clinician. Given the necessity of excluding other etiologies of liver disease, NAFLD can at times represent a challenging diagnosis as non-invasive assessment and biopsy are imperfect tests with important limitations. Similarly, cautious review of laboratory reports is necessary to avoid missing abnormal pathophysiology. The presence of lab values within the standard reference range may be concerning in the setting of chronic liver disease (“abnormally normal”) and conversely results flagged as abnormal may not necessarily be of great concern (“normally abnormal”). This review provides a framework for the clinician to review common diagnostic challenges in NAFLD and enhance patient care.

Keywords

Nonalcoholic fatty liver disease / fibrosis / cryptogenic cirrhosis / sarcopenia / autoantibodies

References

[1] Younossi ZM,Abdelatif D,Henry L.Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.Hepatology2016;64:73-84

[2] Scaglione S,Cao G.The epidemiology of cirrhosis in the United States: A Population-based Study.J Clin Gastroenterol2015;49:690-6

[3] Pais R,Calmus Y.NAFLD and liver transplantation: Current burden and expected challenges.J Hepatol2016;65:1245-57 PMCID:PMC5326676

[4] Francque SM,Kwanten WJ.Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implications.J Hepatol2016;65:425-43

[5] Ratziu V,Heurtier A.LIDO Study GroupSampling variability of liver biopsy in nonalcoholic fatty liver disease.Gastroenterology2005;128:1898-906

[6] Ozturk A,Gee MS.Quantitative hepatic fat quantification in non-alcoholic fatty liver disease using ultrasound-based techniques: a review of literature and their diagnostic performance.Ultrasound Med Biol2018;44:2461-75 PMCID:PMC6628698

[7] Hagström H,Ekstedt M.Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD.J Hepatol2017;67:1265-73

[8] Ballestri S,Baldelli E.Liver fibrosis biomarkers accurately exclude advanced fibrosis and are associated with higher cardiovascular risk scores in patients with NAFLD or viral chronic liver disease.Diagnostics (Basel)2021;11:98 PMCID:PMC7827076

[9] McPherson S,Henderson E,Day CP.Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease.Gut2010;59:1265-9

[10] McPherson S,Dufour JF.Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis.Am J Gastroenterol2017;112:740-51 PMCID:PMC5418560

[11] Doycheva I,Allende D,Watt KD.Low utility of noninvasive fibrosis scores in young adults with nonalcoholic fatty liver disease.Am J Gastroenterol2017;112:652-3

[12] Castera L.Non-invasive tests for liver fibrosis in NAFLD: creating pathways between primary healthcare and liver clinics.Liver Int2020;40 Suppl 1:77-81

[13] Tapper EB,Nasser I,Lai M.The performance of vibration controlled transient elastography in a US cohort of patients with nonalcoholic fatty liver disease.Am J Gastroenterol2016;111:677-84 PMCID:PMC4860094

[14] Chang PE,Ngu JH,Tan CK.Clinical applications, limitations and future role of transient elastography in the management of liver disease.World J Gastrointest Pharmacol Ther2016;7:91-106 PMCID:PMC4734958

[15] Eddowes PJ,Allison M.Accuracy of fibroscan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease.Gastroenterology2019;156:1717-30

[16] Şirli R,Deleanu A.Comparison between the M and XL probes for liver fibrosis assessment by transient elastography.Med Ultrason2014;16:119-22

[17] Loomba R.Advances in non-invasive assessment of hepatic fibrosis.Gut2020;69:1343-52 PMCID:PMC7945956

[18] Newsome PN,Deeks JJ.FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study.Lancet Gastroenterol Hepatol2020;5:362-73 PMCID:PMC7066580

[19] Chalasani N,Lavine JE.The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases.Hepatology2018;67:328-57

[20] Ye Q,Yeo YH.Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis.Lancet Gastroenterol Hepatol2020;5:739-52

[21] Ampuero J,Gallego-Durán R.HEPAmet RegistryThe effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity.Aliment Pharmacol Ther2018;48:1260-70

[22] Gunn NT.The use of liver biopsy in nonalcoholic fatty liver disease: when to biopsy and in whom.Clin Liver Dis2018;22:109-19

[23] Jemal A,Center MM,Ward E.Global cancer statistics.CA Cancer J Clin2011;61:69-90

[24] Stine JG,Zimmet A.Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases.Aliment Pharmacol Ther2018;48:696-703 PMCID:PMC7495494

[25] Marrero JA,Sirlin CB.Diagnosis, staging, and management of hepatocellular carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases.Hepatology2018;68:723-50

[26] Simmons O,Yokoo T.Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis.Aliment Pharmacol Ther2017;45:169-77 PMCID:PMC7207219

[27] Best J,Sowa JP.GALAD score detects early hepatocellular carcinoma in an international cohort of patients with nonalcoholic steatohepatitis.Clin Gastroenterol Hepatol2020;18:728-35.e4

[28] Caldwell SH,Iezzoni JC,Battle EH.Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease.Hepatology1999;29:664-9

[29] Thuluvath PJ,Thuluvath AJ.Is cryptogenic cirrhosis different from NASH cirrhosis?.J Hepatol2018;68:519-25

[30] Caldwell S.Cryptogenic vs. NASH-cirrhosis: The rose exists well before its name.J Hepatol2018;68:391-2

[31] El Atrache MM,Divine G.Recurrence of non-alcoholic steatohepatitis and cryptogenic cirrhosis following orthotopic liver transplantation in the context of the metabolic syndrome.Clin Transplant2012;26:E505-12

[32] Henry ZH.How to identify the patient with nonalcoholic steatohepatitis who will progress to cirrhosis.Gastroenterol Clin North Am2020;49:45-62

[33] Mofrad P,Haque M.Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values.Hepatology2003;37:1286-92

[34] Prati D,Zanella A.Updated definitions of healthy ranges for serum alanine aminotransferase levels.Ann Intern Med2002;137:1-10

[35] Ruhl CE.Upper limits of normal for alanine aminotransferase activity in the United States population.Hepatology2012;55:447-54 PMCID:PMC3268908

[36] Kasarala G.Standard liver tests.Clin Liver Dis (Hoboken)2016;8:13-8 PMCID:PMC6490189

[37] Verma S,Hart J.Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD).Liver Int2013;33:1398-405

[38] Sherman DS,Teitelbaum I.Assessing renal function in cirrhotic patients: problems and pitfalls.Am J Kidney Dis2003;41:269-78

[39] Francoz C.Assessment of renal function in cirrhosis: Sarcopenia, gender and ethnicity matter.J Hepatol2019;70:828-30

[40] Yoo JJ,Kim YS.Estimation of renal function in patients with liver cirrhosis: Impact of muscle mass and sex.J Hepatol2019;70:847-54

[41] Hong HC,Choi HY.Relationship between sarcopenia and nonalcoholic fatty liver disease: the Korean Sarcopenic Obesity Study.Hepatology2014;59:1772-8

[42] Lee YH,Kim SU.Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance: nationwide surveys (KNHANES 2008-2011).J Hepatol2015;63:486-93

[43] Koo BK,Joo SK.Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis.J Hepatol2017;66:123-31

[44] Formica RN,Boyle G.Simultaneous liver-kidney allocation policy: a proposal to optimize appropriate utilization of scarce resources.Am J Transplant2016;16:758-66

[45] Nadelson J,Nair S.Glycated hemoglobin levels in patients with decompensated cirrhosis.Int J Endocrinol2016;2016:8390210 PMCID:PMC5110874

[46] Utzschneider KM.Review: The role of insulin resistance in nonalcoholic fatty liver disease.J Clin Endocrinol Metab2006;91:4753-61

[47] English E,Smith G,Kilpatrick ES.The effect of anaemia and abnormalities of erythrocyte indices on HbA1c analysis: a systematic review.Diabetologia2015;58:1409-21

[48] Tzartzeva K,Rich NE.Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis.Gastroenterology2018;154:1706-18.e1 PMCID:PMC5927818

[49] Tayob N,Do KA.Improved detection of hepatocellular carcinoma by using a longitudinal alpha-fetoprotein screening algorithm.Clin Gastroenterol Hepatol2016;14:469-475.e2 PMCID:PMC4744807

[50] Olivares-Gazca JC,Mendez-Huerta MA,Orea-Martinez JG.More on the thrombocytopenia of the non-alcoholic fatty liver disease.Hematology2017;22:316-9

[51] López-Trujillo MA,Cantero-Fortiz Y.Nonalcoholic fatty liver disease and thrombocytopenia III: its association with insulin resistance.Clin Appl Thromb Hemost2019;25:1076029619888694 PMCID:PMC7019400

[52] Panke CL,Villela-Nogueira CA.Evaluation of thrombocytopenia in patients with non-alcoholic fatty liver disease without cirrhosis.Ann Hepatol2020;19:88-91

[53] Yoneda M,Sumida Y.Japan Study Group of Nonalcoholic Fatty Liver DiseasePlatelet count for predicting fibrosis in nonalcoholic fatty liver disease.J Gastroenterol2011;46:1300-6

[54] Habib A,Abouassi S.High-density lipoprotein cholesterol as an indicator of liver function and prognosis in noncholestatic cirrhotics.Clin Gastroenterol Hepatol2005;3:286-91

[55] Arguello G,Arrese M.Recent insights on the role of cholesterol in non-alcoholic fatty liver disease.Biochim Biophys Acta2015;1852:1765-78

[56] Byrne CD.NAFLD: a multisystem disease.J Hepatol2015;62:S47-64

[57] Kontush A.HDL-mediated mechanisms of protection in cardiovascular disease.Cardiovasc Res2014;103:341-9

[58] Florén CH,Franzén J.Lecithin: cholesterol acyltransferase in liver disease.Scand J Clin Lab Invest1987;47:613-7

[59] Chang L,Barter P.High density lipoprotein subpopulations in chronic liver disease.Hepatology1986;6:46-9

[60] Trifan A,Stanciu C.Update on adrenal insufficiency in patients with liver cirrhosis.World J Gastroenterol2013;19:445-56 PMCID:PMC3558568

[61] Jang JY,Sohn JH.Relative adrenal insufficiency in chronic liver disease: its prevalence and effects on long-term mortality.Aliment Pharmacol Ther2014;40:819-26

[62] Piano S,Tonon M.Including relative adrenal insufficiency in definition and classification of acute-on-chronic liver failure.Clin Gastroenterol Hepatol2020;18:1188-96.e3

[63] Adams LA,Angulo P.The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic Fatty liver disease.Am J Gastroenterol2004;99:1316-20

[64] Loria P,Leonardi F.Non-organ-specific autoantibodies in nonalcoholic fatty liver disease: prevalence and correlates.Dig Dis Sci2003;48:2173-81

[65] Vuppalanchi R,Wilson LA.Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN)Clinical significance of serum autoantibodies in patients with NAFLD: results from the nonalcoholic steatohepatitis clinical research network.Hepatol Int2012;6:379-85 PMCID:PMC3511661

[66] Zhou YJ,Ma HL.Association between positivity of serum autoantibodies and liver disease severity in patients with biopsy-proven NAFLD.Nutr Metab Cardiovasc Dis2021;31:552-60

[67] Konijn AM.5 Iron metabolism in inflammation.Baillieres Clin Haematol1994;7:829-49

[68] Jehn M,Guallar E.Serum ferritin and risk of the metabolic syndrome in U.S. adults.Diabetes Care2004;27:2422-8

[69] Kowdley KV,Wilson LA.NASH Clinical Research NetworkSerum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease.Hepatology2012;55:77-85 PMCID:PMC3245347

[70] Licata A,Cabibbo G.Hyperferritinemia is a risk factor for steatosis in chronic liver disease.World J Gastroenterol2009;15:2132-8 PMCID:PMC2678584

[71] Ruddell RG,Barwood JM.Ferritin functions as a proinflammatory cytokine via iron-independent protein kinase C zeta/nuclear factor kappaB-regulated signaling in rat hepatic stellate cells.Hepatology2009;49:887-900 PMCID:PMC2701483

[72] Walker NM,Ryan RJ.Serum ferritin concentration predicts mortality in patients awaiting liver transplantation.Hepatology2010;51:1683-91

[73] Kowdley KV,Ahn J.ACG Clinical Guideline: hereditary hemochromatosis.Am J Gastroenterol2019;114:1202-18

[74] Gonzalez-Casas R,Moreno-Otero R.Spectrum of anemia associated with chronic liver disease.World J Gastroenterol2009;15:4653-8 PMCID:PMC2754513

[75] Vassiliadis T,Vakalopoulou S.Spur cells and spur cell anemia in hospitalized patients with advanced liver disease: incidence and correlation with disease severity and survival.Hepatol Res2010;40:161-70

[76] Andrès E,Zhu J.The pathophysiology of elevated vitamin B12 in clinical practice.QJM2013;106:505-15

[77] Arendt JF.Unexpected high plasma cobalamin : proposal for a diagnostic strategy.Clin Chem Lab Med2013;51:489-96

[78] Wentworth B.Revisiting vitamin B12 deficiency: A Clinician’s Guide For the 21st Century.Practical Gastroenterology2018;XLII:28-49

[79] Hunt A,Robinson S.Vitamin B12 deficiency.BMJ2014;349:g5226

[80] Teufel A,Kahaly GJ.Concurrent autoimmune diseases in patients with autoimmune hepatitis.J Clin Gastroenterol2010;44:208-13

[81] Niafar M,Porhomayon J.The role of metformin on vitamin B12 deficiency: a meta-analysis review.Intern Emerg Med2015;10:93-102